Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: CN-706, Calydon Inc.

C Doehn1, D Jocham

  • 1Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany. doehn@medinf.mu-luebeck.de

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer].

Urologie (Heidelberg, Germany)·2024
Same author

[Update of the German S3 guideline on renal cell carcinoma].

Urologie (Heidelberg, Germany)·2024
Same author

Der Urologe. Ausg. A·2021
Same author

[Immunotherapy and tyrosine kinase inhibitors in first-line treatment of metastatic renal cell carcinoma-Which strategy when?]

Der Urologe. Ausg. A·2020
Same author

[Algorithms for systemic therapy of prostate cancer, transitional cell carcinoma and renal cell carcinoma].

Der Urologe. Ausg. A·2020
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Calydon is developing CN-706, an engineered adenovirus for prostate cancer treatment. Early trials show promise for this novel gene therapy targeting advanced and recurring prostate cancer.

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Prostate cancer remains a significant health concern, necessitating novel therapeutic strategies.
  • Current treatments for advanced and recurring prostate cancer have limitations.
  • Engineered viruses offer a targeted approach to cancer therapy.

Purpose of the Study:

  • To evaluate the safety and efficacy of CN-706, an oncolytic adenovirus, as a potential treatment for prostate cancer.
  • To assess the clinical development of CN-706, including sponsored trials and patent filings.

Main Methods:

  • CN-706 is an engineered adenovirus incorporating the prostate tissue-specific enhancer (PSE) gene.
  • Phase I and Phase I/II clinical trials were conducted in patients with advanced and recurring prostate cancer.

Related Experiment Videos

  • The technology involves engineering viruses to selectively replicate and induce cell death in prostate cancer cells.

    • Main Results:

    • Phase I trials commenced in 1998 at Johns Hopkins Hospital.
    • Results from phase I/II trials were reported in 2000.
    • Calydon secured multiple US patents for its viral engineering technology.

    Conclusions:

    • CN-706 represents a promising therapeutic candidate for prostate cancer.
    • The development of CN-706 highlights advancements in oncolytic virotherapy.
    • Ongoing clinical trials and patent approvals underscore the potential of this innovative approach.